ClinicalTrials.gg
Status unknownNCT04221152EMPIRE-02Updated Jun 3, 2021

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

A Phase 3 interventional study of Empagliflozin Tablets in Insulin Resistance - Type A, Insulin Resistance - Type B and Lipoatrophic Diabetes Mellitus, sponsored by Kobe University. Status unknown at 5 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Kobe University · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.

Read the detailed description

To determine the safety and efficacy of oral administration of empagliflozin 10 mg or 25 mg once daily for 28 weeks (52 weeks of the EMPIRE-01 study) in subjects who participated in the EMPIRE-01 study, which was conducted on refractory diabetes mellitus patients with insulin resistance (insulin resistance syndrome, lipoatrophic diabetes mellitus) in a multicenter, open-label, single-arm, extension study.

02

Conditions studied

  • Insulin Resistance - Type A
  • Insulin Resistance - Type B
  • Lipoatrophic Diabetes Mellitus
  • Insulin Resistance Syndrome

Keywords

  • insulin resistance
  • refractory diabetes mellitus
03

In context

Diabetes Mellitus, Lipoatrophic

31 studies on the registry are indexed under Diabetes Mellitus, Lipoatrophic; none are open to participants now.

This study's enrollment of 8 is below the median of 309 across 30 interventional studies indexed under Diabetes Mellitus, Lipoatrophic.

Browse Diabetes Mellitus, Lipoatrophic studies →

Lead sponsor

Kobe University is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A patient who completed the preceding EMPIRE-01 study and does not meet any discontinuation criteria
  2. A patient who has received sufficient explanation with regard to information such as the objectives and details of this study, expected drug efficacy/pharmacological action and risks, and has given written consent by her/himself

Exclusion criteria

Exclusion Criteria:

  1. A patient with a medical history of acute coronary syndrome (including non-ST-elevation myocardial infarction, ST-elevation myocardial infarction and unstable angina pectoris), stroke or (TIA) within 3 months before obtaining consent
  2. A patient with suspected hepatic dysfunction that either of serum , AST or alkaline phosphatase is exceeding 3-fold of prior to starting extension study treatment (Day 0)
  3. A patient who is receiving a systemic at the time of consent (except for type B)
  4. A patient whose thyroid hormone product dose has been changed within 6 weeks before obtaining consent
  5. A patient with unstable endocrine diseases other than diabetes mellitus
  6. A patient with hemolysis or blood diseases that destabilize erythrocytic cells and other various disorders (e.g., malaria, babesiosis, hemolytic anemia)
  7. A premenopausal female patient (the latest menstruation was within 1 year before obtaining consent), a lactating or pregnant patient, or a patient who may be pregnant (without hysterectomy or ovariectomy) who has no intention to use efficacious defined in this study during the study period and would not agree to receive regular pregnancy tests during the study period
  8. A patient who has experienced alcohol abuse or drug abuse within 3 months before obtaining consent, which may disturb the study participation
  9. A patient who is in the condition that makes it difficult to administer the study drug
  10. A patient with renal dysfunction of (MDRD calculating formula) \<45 mL/min/1.73 m2 prior to starting extension study treatment (Day 0)
  11. A patient who indicates a response to empagliflozin or its , or a patient with lactose-intolerance
  12. A patient with severe ketosis, diabetic coma or precoma, severe infection, perioperative status, or serious trauma
  13. A patient that the investigator and/or coinvestigator, etc., has judged to be ineligible to this study for other reasons
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Treatment of empagliflozin

    The study treatment shall be started from the next day of the Week 24 visit of the EMPIRE-01 study after enrollment. The investigational drug shall be administered at the same dosage as that of the empagliflozin tablet administered from Week 12 to Week 24 of the treatment period in the EMPIRE-01 study. The administration is oral administration with water once daily before or after breakfast.

    Drug: Empagliflozin Tablets

Interventions

  • The administration is oral administration with water before or after breakfast.

    Also known as: BI10773

06

What researchers measure

Primary outcomes

  1. Adverse events, Adverse drug reactions, and Presence/absence of the use of rescue treatment drugs

    Presence/absence of adverse events, adverse drug reactions, and use of rescue treatment drugs

    Time frame: until Week 28 (Week 52 of the EMPIRE-01 study)

Secondary outcomes

  1. HbA1c change rate at Week 28 (Week 52 of the EMPIRE-01 study) of the treatment from baseline

    The HbA1c change rate at Week 28 (52) from baseline is defined as HbA1c change from baseline divided by baseline HbA1c of the EMPIRE-01 study and multiplied by 100.

    Time frame: at Week 28 (Week 52 of the EMPIRE-01 study) of the treatment from baseline

  2. HbA1c change at Week 28 (Week 52 of the EMPIRE-01 study) of the treatment from baseline

    The HbA1c change at Week 28 (52) of the treatment from baseline is defined as the difference in HbA1c levels between Week 28 (52) and baseline of the EMPIRE-01 study.

    Time frame: at Week 28 (Week 52 of the EMPIRE-01 study) of the treatment from baseline

  3. HbA1c at each time point

    The HbA1c at each time point is defined as the HbA1c levels at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.

    Time frame: at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.

  4. Fasting plasma glucose (FPG) at each time point

    The FPG at each time point is defined as the FPG levels at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.

    Time frame: at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.

  5. Fasting plasma glucose (FPG) change at Week 28 (52) of the treatment from baseline

    The FPG change at Week 28 (52) of the treatment from baseline is defined as the difference in the FPG levels between Week 28 (52) and baseline of the EMPIRE-01 study.

    Time frame: between Week 28 (52) and baseline of the EMPIRE-01 study.

  6. Insulin dose at each time point (TDD, TBD)

    The TDD and TBD at each time point are defined as the insulin doses at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.

    Time frame: at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation.

  7. Postprandial glucose for 2 hours over time

    Postprandial glucose for 2 hours shall be measured for 14 days starting from Week 12 (36) by using FreeStyle Librae ProTM.

    Time frame: for 14 days starting from Week 12 (36)

07

Study locations

5 sites
  • Kobe University Hospital
    Kobe, Hyogo 650-0017, Japan
  • Tohoku University Hospita
    Sendai, Miyagi 980-8574, Japan
  • Jichi Medical University Hospital
    Shimotsuke, Tochigi 329-0498, Japan
  • NIhon University Hospital
    Chiyoda-ku, Tokyo 101-8309, Japan
  • Okayama University Hospital
    Okayama, 700-8558, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Feb 2022, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2020
First posted
Jan 9, 2020
StartActual
Feb 1, 2020
Primary completionEst.
Feb 1, 2022
CompletionEst.
May 31, 2022
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04221152
Lead sponsor
Kobe University
Responsible party
Wataru Ogawa (Professor, Division of Diabetes and Endocrinology, Kobe University) — Principal investigator
First posted
Jan 9, 2020
Start date
Feb 1, 2020
Primary completion
Feb 1, 2022 (estimated)
Completion
May 31, 2022 (estimated)
Last update
Jun 3, 2021

Study contacts

Wataru Ogawa
study chair · Kobe University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion